Detection of Circulating Tumor DNA in Patients with Thyroid Nodules
Objective. Detection of circulating tumor DNA (ctDNA) in cancer patients can potentially serve as a noninvasive, sensitive test of disease status. The purpose of this study was to determine the ability to detect BRAF (V600E) mutations in the plasma of patients with thyroid nodules, with the goal of...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Endocrinology |
| Online Access: | http://dx.doi.org/10.1155/2021/8909224 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832561342850007040 |
|---|---|
| author | Krupal B. Patel Nicholas Cormier James Fowler Allison Partridge Julie Theurer Morgan Black Nicole Pinto John Yoo Kevin Fung Danielle MacNeil William Stecho Christopher Howlett Muriel Brackstone John W. Barrett Anthony Nichols |
| author_facet | Krupal B. Patel Nicholas Cormier James Fowler Allison Partridge Julie Theurer Morgan Black Nicole Pinto John Yoo Kevin Fung Danielle MacNeil William Stecho Christopher Howlett Muriel Brackstone John W. Barrett Anthony Nichols |
| author_sort | Krupal B. Patel |
| collection | DOAJ |
| description | Objective. Detection of circulating tumor DNA (ctDNA) in cancer patients can potentially serve as a noninvasive, sensitive test of disease status. The purpose of this study was to determine the ability to detect BRAF (V600E) mutations in the plasma of patients with thyroid nodules, with the goal of distinguishing between benign and malignant nodules. Methods. Consecutive patients with thyroid nodules who consented for surgery were recruited. Plasma samples were obtained preoperatively and one month postoperatively. Quantitative PCR was used to determine the levels of the BRAF (V600E) mutation preoperatively and postoperatively. Results. A total of 109 patients were recruited. On final pathology, 38 (32.8%) patients had benign thyroid nodules, 45 (38.8%) had classical papillary thyroid cancer (PTC), 23 (19.8%) had nonclassical PTC, and 3 (2.6%) had follicular thyroid cancer. 15/109 patients had detectable BRAF (V600E) ctDNA in their preoperative samples—all of them having classical PTC. Higher T-stage and extrathyroidal extension in PTC were associated with positive BRAF (V600E) ctDNA (p<0.05). Eighty-eight pairs of preoperative and postoperative plasma samples were collected and analyzed. Of these eighty-eight paired samples, a total of 13/88 (14.8%) patients had detectable BRAF (V600E) ctDNA in their preoperative samples—all of them having classical PTC. 12 of these 13 patients had no detectable BRAF (V600E) postoperatively, while one remaining patient had a significant decline in his levels (p<0.05). Conclusion. BRAF (V600E) circulating thyroid tumor DNA can be detected in plasma and is correlated with a final diagnosis of the classical variant of PTC. Given that a postoperative drop in BRAF (V600E) ctDNA levels was observed in all cases suggests its utility as a tumor marker. |
| format | Article |
| id | doaj-art-2567bb119caf44adb2a35dc6bbfd248a |
| institution | Kabale University |
| issn | 1687-8337 1687-8345 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Endocrinology |
| spelling | doaj-art-2567bb119caf44adb2a35dc6bbfd248a2025-02-03T01:25:16ZengWileyInternational Journal of Endocrinology1687-83371687-83452021-01-01202110.1155/2021/89092248909224Detection of Circulating Tumor DNA in Patients with Thyroid NodulesKrupal B. Patel0Nicholas Cormier1James Fowler2Allison Partridge3Julie Theurer4Morgan Black5Nicole Pinto6John Yoo7Kevin Fung8Danielle MacNeil9William Stecho10Christopher Howlett11Muriel Brackstone12John W. Barrett13Anthony Nichols14Department of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Pathology, Western University, London, Ontario, CanadaDepartment of Pathology, Western University, London, Ontario, CanadaDepartment of Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaDepartment of Otolaryngology-Head and Neck Surgery, Western University, London, Ontario, CanadaObjective. Detection of circulating tumor DNA (ctDNA) in cancer patients can potentially serve as a noninvasive, sensitive test of disease status. The purpose of this study was to determine the ability to detect BRAF (V600E) mutations in the plasma of patients with thyroid nodules, with the goal of distinguishing between benign and malignant nodules. Methods. Consecutive patients with thyroid nodules who consented for surgery were recruited. Plasma samples were obtained preoperatively and one month postoperatively. Quantitative PCR was used to determine the levels of the BRAF (V600E) mutation preoperatively and postoperatively. Results. A total of 109 patients were recruited. On final pathology, 38 (32.8%) patients had benign thyroid nodules, 45 (38.8%) had classical papillary thyroid cancer (PTC), 23 (19.8%) had nonclassical PTC, and 3 (2.6%) had follicular thyroid cancer. 15/109 patients had detectable BRAF (V600E) ctDNA in their preoperative samples—all of them having classical PTC. Higher T-stage and extrathyroidal extension in PTC were associated with positive BRAF (V600E) ctDNA (p<0.05). Eighty-eight pairs of preoperative and postoperative plasma samples were collected and analyzed. Of these eighty-eight paired samples, a total of 13/88 (14.8%) patients had detectable BRAF (V600E) ctDNA in their preoperative samples—all of them having classical PTC. 12 of these 13 patients had no detectable BRAF (V600E) postoperatively, while one remaining patient had a significant decline in his levels (p<0.05). Conclusion. BRAF (V600E) circulating thyroid tumor DNA can be detected in plasma and is correlated with a final diagnosis of the classical variant of PTC. Given that a postoperative drop in BRAF (V600E) ctDNA levels was observed in all cases suggests its utility as a tumor marker.http://dx.doi.org/10.1155/2021/8909224 |
| spellingShingle | Krupal B. Patel Nicholas Cormier James Fowler Allison Partridge Julie Theurer Morgan Black Nicole Pinto John Yoo Kevin Fung Danielle MacNeil William Stecho Christopher Howlett Muriel Brackstone John W. Barrett Anthony Nichols Detection of Circulating Tumor DNA in Patients with Thyroid Nodules International Journal of Endocrinology |
| title | Detection of Circulating Tumor DNA in Patients with Thyroid Nodules |
| title_full | Detection of Circulating Tumor DNA in Patients with Thyroid Nodules |
| title_fullStr | Detection of Circulating Tumor DNA in Patients with Thyroid Nodules |
| title_full_unstemmed | Detection of Circulating Tumor DNA in Patients with Thyroid Nodules |
| title_short | Detection of Circulating Tumor DNA in Patients with Thyroid Nodules |
| title_sort | detection of circulating tumor dna in patients with thyroid nodules |
| url | http://dx.doi.org/10.1155/2021/8909224 |
| work_keys_str_mv | AT krupalbpatel detectionofcirculatingtumordnainpatientswiththyroidnodules AT nicholascormier detectionofcirculatingtumordnainpatientswiththyroidnodules AT jamesfowler detectionofcirculatingtumordnainpatientswiththyroidnodules AT allisonpartridge detectionofcirculatingtumordnainpatientswiththyroidnodules AT julietheurer detectionofcirculatingtumordnainpatientswiththyroidnodules AT morganblack detectionofcirculatingtumordnainpatientswiththyroidnodules AT nicolepinto detectionofcirculatingtumordnainpatientswiththyroidnodules AT johnyoo detectionofcirculatingtumordnainpatientswiththyroidnodules AT kevinfung detectionofcirculatingtumordnainpatientswiththyroidnodules AT daniellemacneil detectionofcirculatingtumordnainpatientswiththyroidnodules AT williamstecho detectionofcirculatingtumordnainpatientswiththyroidnodules AT christopherhowlett detectionofcirculatingtumordnainpatientswiththyroidnodules AT murielbrackstone detectionofcirculatingtumordnainpatientswiththyroidnodules AT johnwbarrett detectionofcirculatingtumordnainpatientswiththyroidnodules AT anthonynichols detectionofcirculatingtumordnainpatientswiththyroidnodules |